Alpine Signs an Exclusive License and Collaboration Agreement with Horizon to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Shots:
- Alpine to receive $25M up front, $15M as an equity investment representing a premium of 25% to 30-day share price & is eligible to receive ~$1.52B which includes ~$381M/program upon achievement of development, regulatory & commercial milestones along with royalties
- The collaboration combines Alpine's discovery platform & expertise with Horizon's drug development & commercialization capabilities to develop protein-based immunotherapies for autoimmune & inflammatory diseases
- Horizon gets exclusive rights to develop & commercialize ~4 preclinical products & will lead development, commercialization activities & costs. Alpine to advance candidate molecule to pre-defined preclinical milestone
Ref: Horizon | Image: Horizon
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com